Corcept Therapeutics Incorporated or Verona Pharma plc: Who Invests More in Innovation?

Corcept vs. Verona: A Decade of R&D Investment

__timestampCorcept Therapeutics IncorporatedVerona Pharma plc
Wednesday, January 1, 2014183720004101058
Thursday, January 1, 20151541900010763215
Friday, January 1, 2016238440005579049
Sunday, January 1, 20174037600032051299
Monday, January 1, 20187524700024482286
Tuesday, January 1, 20198901700043892589
Wednesday, January 1, 202011476400044505000
Friday, January 1, 202111386400079406000
Saturday, January 1, 202213099100049283000
Sunday, January 1, 202318435300017282730
Loading chart...

Unleashing the power of data

Innovation Investment: A Tale of Two Biopharma Companies

In the competitive world of biopharmaceuticals, innovation is key to staying ahead. Corcept Therapeutics Incorporated and Verona Pharma plc have been investing significantly in research and development (R&D) over the past decade. From 2014 to 2023, Corcept Therapeutics has consistently outpaced Verona Pharma in R&D spending, with a peak investment in 2023 that was over 10 times their 2014 expenditure. This represents a staggering growth of approximately 900% in their commitment to innovation. Meanwhile, Verona Pharma has also shown a commendable increase, with their R&D expenses growing by over 300% during the same period. The data highlights Corcept's aggressive strategy in innovation, potentially positioning them as a leader in the field. As these companies continue to invest in groundbreaking therapies, the future of biopharma looks promising.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025